Qualification of Drivers; Exemption Applications; Implantable Cardioverter Defibrillator (ICD), 19567-19568 [2020-07283]
Download as PDF
Federal Register / Vol. 85, No. 67 / Tuesday, April 7, 2020 / Notices
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2019–0230]
Qualification of Drivers; Exemption
Applications; Implantable Cardioverter
Defibrillator (ICD)
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of denials.
AGENCY:
FMCSA announces its
decision to deny applications from five
individuals treated with Implantable
Cardioverter Defibrillators (ICDs) who
requested an exemption from the
Federal Motor Carrier Safety
Regulations (FMCSRs) prohibiting
operation of a commercial motor vehicle
(CMV) in interstate commerce by
persons with a current clinical diagnosis
of myocardial infarction, angina
pectoris, coronary insufficiency,
thrombosis, or any other cardiovascular
disease of a variety known to be
accompanied by syncope (transient loss
of consciousness), dyspnea (shortness of
breath), collapse, or congestive heart
failure.
SUMMARY:
Ms.
Christine A. Hydock, Chief, Medical
Programs Division, (202) 366–4001,
fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200
New Jersey Avenue SE, Room W64–224,
Washington, DC 20590–0001. Office
hours are from 8:30 a.m. to 5 p.m., ET,
Monday through Friday, except Federal
holidays. If you have questions
regarding viewing materials in the
docket, contact Docket Operations, (202)
366–9826.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
khammond on DSKJM1Z7X2PROD with NOTICES
I. Public Participation
A. Viewing Documents and Comments
To view comments, as well as any
documents mentioned in this notice as
being available in the docket, go to
https://www.regulations.gov/
docket?D=FMCSA-2019-0230 and
choose the document to review. If you
do not have access to the internet, you
may view the docket online by visiting
the Docket Management Facility in
Room W12–140 on the ground floor of
the DOT West Building, 1200 New
Jersey Avenue SE, Washington, DC
20590, between 9 a.m. and 5 p.m., ET,
Monday through Friday, except Federal
holidays.
B. Privacy Act
In accordance with 5 U.S.C. 553(c),
DOT solicits comments from the public
VerDate Sep<11>2014
18:22 Apr 06, 2020
Jkt 250001
to better inform its rulemaking process.
DOT posts these comments, without
edit, including any personal information
the commenter provides, to
www.regulations.gov, as described in
the system of records notice (DOT/ALL–
14 FDMS), which can be reviewed at
www.dot.gov/privacy.
II. Background
On November 5, 2019, FMCSA
published a Federal Register notice (84
FR 59672) announcing receipt of
applications from six individuals
treated with ICDs and requested
comments from the public. These six
individuals requested an exemption
from 49 CFR 391.41(b)(4) which
prohibits operation of a CMV in
interstate commerce by persons with a
current clinical diagnosis of myocardial
infarction, angina pectoris, coronary
insufficiency, thrombosis, or any other
cardiovascular disease of a variety
known to be accompanied by syncope,
dyspnea, collapse, or congestive heart
failure. The public comment period
closed on December 5, 2019, and six
comments were received.
FMCSA has evaluated the eligibility
of these applicants and concluded that
granting five of these six exemption
requests would not provide a level of
safety that would be equivalent to, or
greater than, the level of safety that
would be obtained by complying with
§ 391.41(b)(4). One individual’s
application was withdrawn. A summary
of each applicant’s medical history
related to their ICD exemption request
was discussed in the November 5, 2019,
Federal Register notice and will not be
repeated here.
The Agency’s decision regarding these
exemption applications is based on
information from the Cardiovascular
Medical Advisory Criteria, an April
2007, evidence report titled
‘‘Cardiovascular Disease and
Commercial Motor Vehicle Driver
Safety,’’ 1 and a December 2014, focused
research report titled ‘‘Implantable
Cardioverter Defibrillators and the
Impact of a Shock in a Patient When
Deployed.’’ Copies of these reports are
included in the docket.
FMCSA has published advisory
criteria to assist medical examiners in
determining whether drivers with
certain medical conditions are qualified
to operate a CMV in interstate
commerce.2 The advisory criteria for
1 The reports are available on the internet at
https://rosap.ntl.bts.gov/view/dot/16462; https://
rosap.ntl.bts.gov/view/dot/21199.
2 These criteria may be found in 49 CFR part 391,
Appendix A to Part 391—Medical Advisory
Criteria, section D. Cardiovascular: § 391.41(b)(4),
paragraph 4, which is available on the internet at
PO 00000
Frm 00146
Fmt 4703
Sfmt 4703
19567
§ 391.41(b)(4) indicates that coronary
artery bypass surgery and pacemaker
implantation are remedial procedures
and thus, not medically disqualifying.
Implantable cardioverter defibrillators
are disqualifying due to risk of syncope.
III. Discussion of Comments
FMCSA received six comments in this
proceeding. Five of the six comments
were favorable towards the applicants
continuing to drive CMV’s with ICD’s.
The sixth comment was submitted by
Mr. Corey Tugwell’s cardiologist. His
cardiologist’s comments supported the
withdrawal of Mr. Tugwell’s exemption
application.
In response to the comments, FMCSA
believes that a driver with an ICD is at
risk for incapacitation if the device
discharges. This risk is combined with
the risks associated with the underlying
cardiovascular condition for which the
ICD has been implanted as a primary or
secondary preventive measure. Mr.
Tugwell’s application was withdrawn
because an exemption is unnecessary.
Mr. Tugwell was notified that he must
still complete a medical certification
examination by a certified medical
examiner on the National Registry of
Certified Medical Examiners to
determine whether his underlying
cardiovascular condition is stable, and if
he meets the cardiovascular physical
qualification standards (49 CFR
391.41(b)(4)) to receive a medical
examiner’s certificate.
IV. Basis for Exemption Determination
Under 49 U.S.C. 31136(e) and
31315(b), FMCSA may grant an
exemption from the FMCSRs for no
longer than a 5-year period if it finds
such exemption would likely achieve a
level of safety that is equivalent to, or
greater than, the level that would be
achieved absent such exemption.
The Agency’s decision regarding these
exemption applications is based on an
individualized assessment of each
applicant’s medical information,
available medical and scientific data
concerning ICDs, and any relevant
public comments received.
In the case of persons with ICDs, the
underlying condition for which the ICD
was implanted places the individual at
high risk for syncope or other
unpredictable events known to result in
gradual or sudden incapacitation. ICDs
may discharge, which could result in
loss of ability to safely control a CMV.
The December 2014 focused research
report discussed earlier upholds the
findings of the April 2007 report and
https://www.gpo.gov/fdsys/pkg/CFR-2015-title49vol5/pdf/CFR-2015-title49-vol5-part391-appA.pdf.
E:\FR\FM\07APN1.SGM
07APN1
19568
Federal Register / Vol. 85, No. 67 / Tuesday, April 7, 2020 / Notices
indicates that the available scientific
data on persons with ICDs and CMV
driving does not support that persons
with ICDs who operate CMVs are able
to meet an equal or greater level of
safety.
V. Conclusion
The Agency has determined that the
available medical and scientific
literature and research provides
insufficient data to enable the Agency to
conclude that granting these exemptions
would achieve a level of safety
equivalent to, or greater than, the level
of safety maintained without the
exemption. Therefore, the following five
applicants have been denied
exemptions from the physical
qualification standards in § 391.41(b)(4):
Charles Huff (OH)
Brian J. Hullopeter (MN)
John Gittenmeier (MO)
Gaetano Letizia (NJ)
Thomas D. Worsley (VA)
Each applicant has, prior to this
notice, received a letter of final
disposition regarding his/her exemption
request. Those decision letters fully
outlined the basis for the denial and
constitute final action by the Agency.
The list published today summarizes
the Agency’s recent denials as required
under 49 U.S.C. 31315(b)(4).
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2020–07283 Filed 4–6–20; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2020–0046]
I. Public Participation
Qualification of Drivers; Exemption
Applications; Epilepsy and Seizure
Disorders
A. Submitting Comments
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of applications for
exemption; request for comments.
AGENCY:
FMCSA announces receipt of
applications from seven individuals for
an exemption from the prohibition in
the Federal Motor Carrier Safety
Regulations (FMCSRs) against persons
with a clinical diagnosis of epilepsy or
any other condition that is likely to
cause a loss of consciousness or any loss
of ability to control a commercial motor
vehicle (CMV) to drive in interstate
commerce. If granted, the exemptions
would enable these individuals who
have had one or more seizures and are
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:22 Apr 06, 2020
Jkt 250001
taking anti-seizure medication to
operate CMVs in interstate commerce.
DATES: Comments must be received on
or before May 7, 2020.
ADDRESSES: You may submit comments
identified by the Federal Docket
Operations Docket No. FMCSA–2020–
0046 using any of the following
methods:
• Federal eRulemaking Portal: Go to
https://www.regulations.gov/
docket?D=FMCSA-2020-0046. Follow
the online instructions for submitting
comments.
• Mail: Docket Operations; U.S.
Department of Transportation, 1200
New Jersey Avenue SE, West Building
Ground Floor, Room W12–140,
Washington, DC 20590–0001.
• Hand Delivery: West Building
Ground Floor, Room W12–140, 1200
New Jersey Avenue SE, Washington,
DC, between 9 a.m. and 5 p.m., ET,
Monday through Friday, except Federal
Holidays.
• Fax: (202) 493–2251.
To avoid duplication, please use only
one of these four methods. See the
‘‘Public Participation’’ portion of the
SUPPLEMENTARY INFORMATION section for
instructions on submitting comments.
FOR FURTHER INFORMATION CONTACT: Ms.
Christine A. Hydock, Chief, Medical
Programs Division, (202) 366–4001,
fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200
New Jersey Avenue SE, Room W64–224,
Washington, DC 20590–0001. Office
hours are 8:30 a.m. to 5 p.m., ET,
Monday through Friday, except Federal
holidays. If you have questions
regarding viewing or submitting
material to the docket, contact Docket
Operations, (202) 366–9826.
SUPPLEMENTARY INFORMATION:
If you submit a comment, please
include the docket number for this
notice (Docket No. FMCSA–2020–0046),
indicate the specific section of this
document to which each comment
applies, and provide a reason for each
suggestion or recommendation. You
may submit your comments and
material online or by fax, mail, or hand
delivery, but please use only one of
these means. FMCSA recommends that
you include your name and a mailing
address, an email address, or a phone
number in the body of your document
so that FMCSA can contact you if there
are questions regarding your
submission.
To submit your comment online, go to
https://www.regulations.gov/
PO 00000
Frm 00147
Fmt 4703
Sfmt 4703
docket?D=FMCSA-2020-0046. Click on
the ‘‘Comment Now!’’ button and type
your comment into the text box on the
following screen. Choose whether you
are submitting your comment as an
individual or on behalf of a third party
and then submit.
If you submit your comments by mail
or hand delivery, submit them in an
unbound format, no larger than 81⁄2 by
11 inches, suitable for copying and
electronic filing. If you submit
comments by mail and would like to
know that they reached the facility,
please enclose a stamped, self-addressed
postcard or envelope.
FMCSA will consider all comments
and material received during the
comment period.
B. Viewing Documents and Comments
To view comments, as well as any
documents mentioned in this notice as
being available in the docket, go to
https://www.regulations.gov/
docket?D=FMCSA-2020-0046 and
choose the document to review. If you
do not have access to the internet, you
may view the docket online by visiting
the Docket Operations in Room W12–
140 on the ground floor of the DOT
West Building, 1200 New Jersey Avenue
SE, Washington, DC 20590, between 9
a.m. and 5 p.m., ET, Monday through
Friday, except Federal holidays.
C. Privacy Act
In accordance with 5 U.S.C. 553(c),
DOT solicits comments from the public
to better inform its rulemaking process.
DOT posts these comments, without
edit, including any personal information
the commenter provides, to
www.regulations.gov, as described in
the system of records notice (DOT/ALL–
14 FDMS), which can be reviewed at
www.transportation.gov/privacy.
II. Background
Under 49 U.S.C. 31136(e) and
31315(b), FMCSA may grant an
exemption from the FMCSRs for no
longer than a 5-year period if it finds
such exemption would likely achieve a
level of safety that is equivalent to, or
greater than, the level that would be
achieved absent such exemption. The
statute also allows the Agency to renew
exemptions at the end of the 5-year
period. FMCSA grants medical
exemptions from the FMCSRs for a 2year period to align with the maximum
duration of a driver’s medical
certification.
The seven individuals listed in this
notice have requested an exemption
from the epilepsy and seizure disorders
prohibition in 49 CFR 391.41(b)(8).
Accordingly, the Agency will evaluate
E:\FR\FM\07APN1.SGM
07APN1
Agencies
[Federal Register Volume 85, Number 67 (Tuesday, April 7, 2020)]
[Notices]
[Pages 19567-19568]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-07283]
[[Page 19567]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2019-0230]
Qualification of Drivers; Exemption Applications; Implantable
Cardioverter Defibrillator (ICD)
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.
ACTION: Notice of denials.
-----------------------------------------------------------------------
SUMMARY: FMCSA announces its decision to deny applications from five
individuals treated with Implantable Cardioverter Defibrillators (ICDs)
who requested an exemption from the Federal Motor Carrier Safety
Regulations (FMCSRs) prohibiting operation of a commercial motor
vehicle (CMV) in interstate commerce by persons with a current clinical
diagnosis of myocardial infarction, angina pectoris, coronary
insufficiency, thrombosis, or any other cardiovascular disease of a
variety known to be accompanied by syncope (transient loss of
consciousness), dyspnea (shortness of breath), collapse, or congestive
heart failure.
FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division, (202) 366-4001, [email protected], FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224,
Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m.,
ET, Monday through Friday, except Federal holidays. If you have
questions regarding viewing materials in the docket, contact Docket
Operations, (202) 366-9826.
SUPPLEMENTARY INFORMATION:
I. Public Participation
A. Viewing Documents and Comments
To view comments, as well as any documents mentioned in this notice
as being available in the docket, go to https://www.regulations.gov/docket?D=FMCSA-2019-0230 and choose the document to review. If you do
not have access to the internet, you may view the docket online by
visiting the Docket Management Facility in Room W12-140 on the ground
floor of the DOT West Building, 1200 New Jersey Avenue SE, Washington,
DC 20590, between 9 a.m. and 5 p.m., ET, Monday through Friday, except
Federal holidays.
B. Privacy Act
In accordance with 5 U.S.C. 553(c), DOT solicits comments from the
public to better inform its rulemaking process. DOT posts these
comments, without edit, including any personal information the
commenter provides, to www.regulations.gov, as described in the system
of records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.dot.gov/privacy.
II. Background
On November 5, 2019, FMCSA published a Federal Register notice (84
FR 59672) announcing receipt of applications from six individuals
treated with ICDs and requested comments from the public. These six
individuals requested an exemption from 49 CFR 391.41(b)(4) which
prohibits operation of a CMV in interstate commerce by persons with a
current clinical diagnosis of myocardial infarction, angina pectoris,
coronary insufficiency, thrombosis, or any other cardiovascular disease
of a variety known to be accompanied by syncope, dyspnea, collapse, or
congestive heart failure. The public comment period closed on December
5, 2019, and six comments were received.
FMCSA has evaluated the eligibility of these applicants and
concluded that granting five of these six exemption requests would not
provide a level of safety that would be equivalent to, or greater than,
the level of safety that would be obtained by complying with Sec.
391.41(b)(4). One individual's application was withdrawn. A summary of
each applicant's medical history related to their ICD exemption request
was discussed in the November 5, 2019, Federal Register notice and will
not be repeated here.
The Agency's decision regarding these exemption applications is
based on information from the Cardiovascular Medical Advisory Criteria,
an April 2007, evidence report titled ``Cardiovascular Disease and
Commercial Motor Vehicle Driver Safety,'' \1\ and a December 2014,
focused research report titled ``Implantable Cardioverter
Defibrillators and the Impact of a Shock in a Patient When Deployed.''
Copies of these reports are included in the docket.
---------------------------------------------------------------------------
\1\ The reports are available on the internet at https://rosap.ntl.bts.gov/view/dot/16462; https://rosap.ntl.bts.gov/view/dot/21199.
---------------------------------------------------------------------------
FMCSA has published advisory criteria to assist medical examiners
in determining whether drivers with certain medical conditions are
qualified to operate a CMV in interstate commerce.\2\ The advisory
criteria for Sec. 391.41(b)(4) indicates that coronary artery bypass
surgery and pacemaker implantation are remedial procedures and thus,
not medically disqualifying. Implantable cardioverter defibrillators
are disqualifying due to risk of syncope.
---------------------------------------------------------------------------
\2\ These criteria may be found in 49 CFR part 391, Appendix A
to Part 391--Medical Advisory Criteria, section D. Cardiovascular:
Sec. 391.41(b)(4), paragraph 4, which is available on the internet
at https://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/CFR-2015-title49-vol5-part391-appA.pdf.
---------------------------------------------------------------------------
III. Discussion of Comments
FMCSA received six comments in this proceeding. Five of the six
comments were favorable towards the applicants continuing to drive
CMV's with ICD's. The sixth comment was submitted by Mr. Corey
Tugwell's cardiologist. His cardiologist's comments supported the
withdrawal of Mr. Tugwell's exemption application.
In response to the comments, FMCSA believes that a driver with an
ICD is at risk for incapacitation if the device discharges. This risk
is combined with the risks associated with the underlying
cardiovascular condition for which the ICD has been implanted as a
primary or secondary preventive measure. Mr. Tugwell's application was
withdrawn because an exemption is unnecessary. Mr. Tugwell was notified
that he must still complete a medical certification examination by a
certified medical examiner on the National Registry of Certified
Medical Examiners to determine whether his underlying cardiovascular
condition is stable, and if he meets the cardiovascular physical
qualification standards (49 CFR 391.41(b)(4)) to receive a medical
examiner's certificate.
IV. Basis for Exemption Determination
Under 49 U.S.C. 31136(e) and 31315(b), FMCSA may grant an exemption
from the FMCSRs for no longer than a 5-year period if it finds such
exemption would likely achieve a level of safety that is equivalent to,
or greater than, the level that would be achieved absent such
exemption.
The Agency's decision regarding these exemption applications is
based on an individualized assessment of each applicant's medical
information, available medical and scientific data concerning ICDs, and
any relevant public comments received.
In the case of persons with ICDs, the underlying condition for
which the ICD was implanted places the individual at high risk for
syncope or other unpredictable events known to result in gradual or
sudden incapacitation. ICDs may discharge, which could result in loss
of ability to safely control a CMV. The December 2014 focused research
report discussed earlier upholds the findings of the April 2007 report
and
[[Page 19568]]
indicates that the available scientific data on persons with ICDs and
CMV driving does not support that persons with ICDs who operate CMVs
are able to meet an equal or greater level of safety.
V. Conclusion
The Agency has determined that the available medical and scientific
literature and research provides insufficient data to enable the Agency
to conclude that granting these exemptions would achieve a level of
safety equivalent to, or greater than, the level of safety maintained
without the exemption. Therefore, the following five applicants have
been denied exemptions from the physical qualification standards in
Sec. 391.41(b)(4):
Charles Huff (OH)
Brian J. Hullopeter (MN)
John Gittenmeier (MO)
Gaetano Letizia (NJ)
Thomas D. Worsley (VA)
Each applicant has, prior to this notice, received a letter of
final disposition regarding his/her exemption request. Those decision
letters fully outlined the basis for the denial and constitute final
action by the Agency. The list published today summarizes the Agency's
recent denials as required under 49 U.S.C. 31315(b)(4).
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2020-07283 Filed 4-6-20; 8:45 am]
BILLING CODE 4910-EX-P